UNCY · Unicycive Therapeutics, Inc. · Metrics
$3.93
+0.13 (+3.42%)
At close · Oct 21
Return incl. dividend (before tax)
Market Cap
$110.45M
Shares
27.86M
Volume · Oct 21
1.44M
Avg daily vol (3M)
864.13K
UNCY metrics
60 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$3.87
Market cap
$110.45M
Price action
20 metricsPrice change (1W)
+1.9%
Price change (30D)
-20.3%
Price change (3M)
-33.2%
Price change (6M)
-47.3%
Price change (YTD)
-34.1%
Price change (1Y)
-24.0%
Trailing year
Price change (5Y)
—
52-week high
$8.56
52-week low
$3.36
Change from 52-week high
-55.6%
Change from 52-week low
+13.1%
Annualized volatility
78.8%
Annualized volatility (3M)
58.0%
Beta
1.0
RSI (14D)
37.1
Price vs SMA 50
-20.9%
Price vs SMA 200
-38.6%
Avg volume (3M)
859,540
Relative volume
1.4
Average dollar volume
$4.13M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
27.86M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.9
reciprocal yield 52.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-34.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-3,077.6%
Trailing 12 months
Net margin
-4,525.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$33.14M
Net income (TTM)
−$35.22M
Trailing 12 months
Diluted EPS (TTM)
$-1.25
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-29.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+118.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-66.1%
Return on assets
-48.9%
Debt / equity
0.0
Current ratio
3.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$61.42M
Latest balance sheet
Cash & equivalents
$44.19M
Total assets
$72.03M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$27.84M
Capital expenditures (TTM)
$9,000
R&D (TTM)
$9.60M
SG&A (TTM)
$701,000
Stock compensation (TTM)
$5.14M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
79
13F filer change QoQ
+28
Institutional ownership
50.0%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
25.0%
Private-fund adviser ownership
21.0%
Active holders' share change QoQ
-12.4%
Holder tenure
7.3
Price vs estimated holder cost
-30.5%
Ownership (registered funds)
1 metricsIndex-fund ownership
8.3%
Short interest
3 metricsShort interest
17.4%
Latest settlement · 5.7 days to cover
Days to cover
5.7d
Short-squeeze score
66 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—